GB virus C genotype determination in GB virus-C/HIV co-infected individuals

被引:50
作者
Muerhoff, AS
Tillmann, HL
Manns, MP
Dawson, GJ
Desai, SM
机构
[1] Abbott Labs, Abbott Diagnost Div, Abbott Pk, IL 60064 USA
[2] Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, Hannover, Germany
关键词
GB viruses; phylogenetic analysis; human immunodeficiency virus; CD4; cells; survival; AIDS;
D O I
10.1002/jmv.10375
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Several recent studies have indicated that patients infected with human immunodeficiency virus (HIV) exhibit a beneficial effect of co-infection with GB virus C (GBV-C). The benefit is demonstrated by slower progression to acquired immunodeficiency syndrome (AIDS) and prolonged survival time after the development of AIDS. In some but not all studies, a significant association between GBV-C/HIV co-infection and increased CD4(+) cell counts has been reported. To understand further the possible role that GBV-C might play in the reduced morbidity and mortality among HIV-infected patients, we sought to examine the presence of different GBV-C genotypes in a cohort of co-infected patients. PCR products derived from the 5'-untranslated region (5'-UTR) and the second envelope gene (E2) were sequenced directly and genotyped by phylogenetic analysis. While 5'-UTR analysis delineated the major type, analysis of the complete E2 gene was required for identification of group 2 sub-types, designated 2a and 2b. Among 35 patients tested, GBV-C genotype was determined for 33: two patients were infected with genotype 1, 12 with type 2a, and 19 with type 2b. Clinical data were available for 25 genotyped patients: one infected with genotype 1, nine with genotype 2a, and 15 with type 2b. CD4(+) cell counts tended to be lower in patients infected with genotype 2a compared with those with genotype 2b (310 +/- 136 vs 430 +/- 199, P = 0.054). Additional studies with larger cohorts from separate geographical regions are needed to determine whether a particular GBV-C genotype is associated with reduced morbidity or mortality among HIV co-infected patients. (C) 2003 Wiley-Liss, Inc.
引用
收藏
页码:141 / 149
页数:9
相关论文
共 69 条
[1]  
Aronoff DM, 2002, ANTIVIR THER, V7, P73
[2]   Increased plasma human immunodeficiency virus type 1 burden following antigenic challenge with pneumococcal vaccine [J].
Brichacek, B ;
Swindells, S ;
Janoff, EN ;
Pirruccello, S ;
Stevenson, M .
JOURNAL OF INFECTIOUS DISEASES, 1996, 174 (06) :1191-1199
[3]   COINFECTION OF HEPATITIS-C VIRUS WITH HUMAN-IMMUNODEFICIENCY-VIRUS AND PROGRESSION TO AIDS [J].
DORRUCCI, M ;
PEZZOTTI, P ;
PHILLIPS, AN ;
LEPRI, AC ;
REZZA, G .
JOURNAL OF INFECTIOUS DISEASES, 1995, 172 (06) :1503-1508
[4]  
Elvander M, 1998, ACTA VET SCAND, V39, P251
[5]  
Felsenstein J., 1993, PHYLIP PHYLOGENY INF
[6]   Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. [J].
Fried, MW ;
Shiffman, ML ;
Reddy, KR ;
Smith, C ;
Marinos, G ;
Goncales, FL ;
Haussinger, D ;
Diago, M ;
Carosi, G ;
Dhumeaux, D ;
Craxi, A ;
Lin, A ;
Hoffman, J ;
Yu, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (13) :975-982
[7]   Suppression of CCR5-but not CXCR4-tropic HIV-1 in lymphoid tissue by human herpesvirus 6 [J].
Grivel, JC ;
Ito, Y ;
Fagà, G ;
Santoro, F ;
Shaheen, F ;
Malnati, MS ;
Fitzgerald, W ;
Lusso, P ;
Margolis, L .
NATURE MEDICINE, 2001, 7 (11) :1232-1235
[8]  
Hassoba HM, 1998, J MED VIROL, V56, P253, DOI 10.1002/(SICI)1096-9071(199811)56:3&lt
[9]  
253::AID-JMV13&gt
[10]  
3.0.CO